CELLBXHEALTH PLC (CLBX) — Preliminary results for the year ended 31 December 2025

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the CELLBX Health PLC Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and can be submitted at any time via the Q and A tab situated on the right hand corner of your screen. Just simply type in your questions and press send. Before we begin, I'd like to submit the following poll. And I'd like to hand you over to Peter Collins, CEO. Good morning, sir. Thank you. Good morning, everybody. Peter Collins, CEO at CELLBXHEALTH. I'm joined this morning by our executive chairman, Jan Groen, and our head of finance, Sinead Armstrong. So let's get moving. So key highlights about CELLBX and the exciting opportunity in front of us and the the the reason, I guess, everyone's gathered here. We have a key platform for better understanding of cancer biology, identifying patients who would benefit from important therapies and to enable drug companies to develop more therapies to to address a huge number of unmet clinical needs in the oncology space. So well established with a leading platform with high recovery and viability rates. We understand very well now that in a in a in a blood test, ctDNA falls short in many areas and only via circulating tumor cells can you address the full picture in a multiomic analysis of what's coming or or what's the characteristics of the tumor. Well established on three commercial pillars of instruments consumables. A farmer and CRO services business plus laboratory developed tests, we've got a significant installed base across academia and and globally. We've put in place some anchor pharma and clinical partnerships since our reset at the end of twenty twenty five and beginning of twenty six. Recent announcements you'll have seen with the master s...